These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 26922873)

  • 1. Amylin-mediated control of glycemia, energy balance, and cognition.
    Mietlicki-Baase EG
    Physiol Behav; 2016 Aug; 162():130-40. PubMed ID: 26922873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.
    Adler BL; Yarchoan M; Hwang HM; Louneva N; Blair JA; Palm R; Smith MA; Lee HG; Arnold SE; Casadesus G
    Neurobiol Aging; 2014 Apr; 35(4):793-801. PubMed ID: 24239383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of food intake and energy expenditure by amylin-therapeutic implications.
    Lutz TA
    Int J Obes (Lond); 2009 Apr; 33 Suppl 1():S24-7. PubMed ID: 19363503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology.
    Roth JD
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):8-13. PubMed ID: 23183359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control.
    Ladenheim EE
    Curr Opin Endocrinol Diabetes Obes; 2012 Feb; 19(1):13-8. PubMed ID: 22157396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amylin activates distributed CNS nuclei to control energy balance.
    Mietlicki-Baase EG; Hayes MR
    Physiol Behav; 2014 Sep; 136():39-46. PubMed ID: 24480072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amylin in Alzheimer's disease: Pathological peptide or potential treatment?
    Mietlicki-Baase EG
    Neuropharmacology; 2018 Jul; 136(Pt B):287-297. PubMed ID: 29233636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
    Edelman SV; Weyer C
    Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraneuronal Amylin Deposition, Peroxidative Membrane Injury and Increased IL-1β Synthesis in Brains of Alzheimer's Disease Patients with Type-2 Diabetes and in Diabetic HIP Rats.
    Verma N; Ly H; Liu M; Chen J; Zhu H; Chow M; Hersh LB; Despa F
    J Alzheimers Dis; 2016 May; 53(1):259-72. PubMed ID: 27163815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide.
    Mack CM; Smith PA; Athanacio JR; Xu K; Wilson JK; Reynolds JM; Jodka CM; Lu MG; Parkes DG
    Diabetes Obes Metab; 2011 Dec; 13(12):1105-13. PubMed ID: 21733060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition.
    Grizzanti J; Corrigan R; Casadesus G
    J Alzheimers Dis; 2018; 66(1):11-23. PubMed ID: 30282360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake.
    Mietlicki-Baase EG; Olivos DR; Jeffrey BA; Hayes MR
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1116-22. PubMed ID: 25898952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC; Grasso P
    Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing diabetes treatment using an amylin analogue.
    Edelman SV
    Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
    Liberini CG; Koch-Laskowski K; Shaulson E; McGrath LE; Lipsky RK; Lhamo R; Ghidewon M; Ling T; Stein LM; Hayes MR
    Sci Rep; 2019 Jun; 9(1):8447. PubMed ID: 31186439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment.
    Corrigan RR; Piontkivska H; Casadesus G
    Curr Neuropharmacol; 2022; 20(10):1894-1907. PubMed ID: 34852745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pramlintide on energy intake and food preference in rats given a choice diet.
    Kern KA; DiBrog AM; Przybysz JT; Mietlicki-Baase EG
    Physiol Behav; 2021 Oct; 240():113541. PubMed ID: 34332974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
    Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
    Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats.
    Stein LM; McGrath LE; Lhamo R; Koch-Laskowski K; Fortin SM; Skarbaliene J; Baader-Pagler T; Just R; Hayes MR; Mietlicki-Baase EG
    Am J Physiol Regul Integr Comp Physiol; 2021 Aug; 321(2):R250-R259. PubMed ID: 34259025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of amylin and amylin deficiency.
    Kruger DF; Gatcomb PM; Owen SK
    Diabetes Educ; 1999; 25(3):389-97; quiz 398. PubMed ID: 10531859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.